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Transcriptional dysregulation of 
Interferome in experimental and 
human Multiple Sclerosis
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Rosella Mechelli4, Vittorio Martinelli1, Paul Hertzog5, Marco Salvetti4,6, Roberto Furlan  1, 
Gianvito Martino  1,2, Giancarlo Comi1,2, Eliana M. Coccia3 & Cinthia Farina1
Recent evidence indicates that single multiple sclerosis (MS) susceptibility genes involved in interferon 
(IFN) signaling display altered transcript levels in peripheral blood of untreated MS subjects, suggesting 
that responsiveness to endogenous IFN is dysregulated during neuroinflammation. To prove this 
hypothesis we exploited the systematic collection of IFN regulated genes (IRG) provided by the 
Interferome database and mapped Interferome changes in experimental and human MS. Indeed, 
central nervous system tissue and encephalitogenic CD4 T cells during experimental autoimmune 
encephalomyelitis were characterized by massive changes in Interferome transcription. Further, the 
analysis of almost 500 human blood transcriptomes showed that (i) several IRG changed expression at 
distinct MS stages with a core of 21 transcripts concordantly dysregulated in all MS forms compared 
with healthy subjects; (ii) 100 differentially expressed IRG were validated in independent case-control 
cohorts; and (iii) 53 out of 100 dysregulated IRG were targeted by IFN-beta treatment in vivo. Finally, 
ex vivo and in vitro experiments established that IFN-beta administration modulated expression 
of two IRG, ARRB1 and CHP1, in immune cells. Our study confirms the impairment of Interferome 
in experimental and human MS, and describes IRG signatures at distinct disease stages which can 
represent novel therapeutic targets in MS.
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central nervous system (CNS) 
presenting with unpredictable and heterogeneous clinical courses. The first clinical occurrence of neurological 
dysfunction with features suggestive of a demyelinating inflammatory event is termed clinically isolated syn-
drome (CIS)1. The most frequent clinical course of MS, the relapsing-remitting form (RR-MS), is characterized 
by periodic worsening of the neurological condition followed by partial or complete remission. After several years 
most of the RR-MS patients develop the secondary progressive course (SP-MS) with advancing neurological dys-
function without recognizable relapses1. In a small fraction of MS subjects the progressive form of the disease is 
seen from onset and is referred as primary progressive (PP-MS). MS is a complex disorder where several genetic 
and environmental factors are involved2. The most recent high-throughput genetic screening in MS has high-
lighted that many genetic risk variants are located in the vicinity of immunologically relevant genes3. Interestingly 
these genes include several IRG, like TYK2, OAS1, STAT3 and STAT4, suggesting the genetically determined dys-
function of the pathways regulated by interferons in MS. Interferons (IFN) are a major class of proteins released 
by the host in response to pathogens, with IFN-beta being involved in antiviral defense4. Notably, the administra-
tion of recombinant IFN-beta is a first-line treatment for RR-MS5, indicating that the stimulation of that pathway 
in vivo is beneficial to MS patients. Our hypothesis is that MS is characterized by dysregulation of the genes 
involved in IFN signaling. To demonstrate it we (1) recovered IRG from the Interferome database, which collects 
and analyzes publicly available gene expression experiments where cells were exposed to IFN, (2) systematically 
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checked their expression and enrichment in immune cells and/or CNS of human or experimental MS, and (3) 
verified their modulation by IFN-beta in vivo and in vitro.
Results
Transcriptomic analysis of Interferome in experimental MS. To investigate the expression levels 
of the genes regulated by interferons during experimental neuroinflammation, we performed high-throughput 
transcriptomic profiling of spinal cord tissues isolated from EAE mice at day 20 and 40 post-immunization (dpi) 
and age-matched naïve control animals. At the same time we queried Interferome, a manually curated, systematic 
collection of IRG identified in published transcriptomics studies, to retrieve 4081 mouse IRG, which were then 
mapped to the corresponding Affymetrix probes using biomaRt ID conversion package in R Bioconductor (see 
workflow in Fig. 1A). After preprocessing and intensity filter, we examined whether 4022 Affymetrix probes 
corresponding to 2523 IRG were differentially expressed in the spinal cord of EAE mice at 20 and 40 dpi com-
pared to control samples from naïve mice. A total of 575 and 858 IRG probes was dysregulated at 20 and 40 dpi 
respectively (Supplementary Table 2) with most of the IRG up-or down-regulated in EAE mice at 20 dpi appear-
ing also at 40 dpi (Fig. 1C), including the upregulation of MHC molecules, chemotactic mediators (CXCL10, 
CCL5, CCL6, CXCL12), typical IFN-induced proteins (GBP proteins) and transcription factors (IFN regulatory 
transcription factor (IRF)8, IRF9, signal transducer and activator of transcription (STAT)1, STAT3). To verify 
whether Interferome elements were enriched in the CNS transcriptome of EAE animals, we measured the fre-
quency of differential expression (DE) among IRG and compared it to the frequency of dysregulation in the global 
transcriptome by chi-square and z-score statistics. We found that the frequency of dysregulation in IRG in the 
CNS of EAE animals at 20 and 40 dpi was significantly higher than the expected frequency of dysregulation in a 
random selection of transcripts (Table 1).
Next, we investigated the expression levels of Interferome specifically in mouse CD4+ T cells during EAE 
or in vitro differentiation. The study by Hoppmann et al.6 generated transcriptomes from myelin-specific 
CD4+CD62L+T lymphocytes before (T naïve) and after in vitro Th17 differentiation (Th17 iv), myelin-reactive 
Figure 1. (A) Flow chart for the transcriptomics study of mouse spinal cord. (B) Flow chart for the 
transcriptomics study of mouse CD4 T lymphocytes. (C) Number of common and unique dysregulated IRG in 
EAE spinal cord (SC) at day 20 and 40 post immunization. (D) Number of common and unique dysregulated 
IRG in CD4eae and Th17eae T lymphocytes. (E) Number of common and unique IRG DEG in Th17iv and 
Th17eae T lymphocytes.
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CD4+Th17 T lymphocytes isolated from the CNS of EAE mice after adoptive transfer (Th17eae), and CD4+T 
lymphocytes isolated from the CNS of EAE mice after active immunization (CD4eae)6. Thus, we retrieved the 
global transcriptome and isolated the expression values of IRG probes in T naïve, Th17iv, Th17eae, and CD4eae. 
As shown in Fig. 1B, there were 4147 Agilent probes corresponding to 2990 IRG passing the intensity filter cri-
teria. Similarly to the CNS analysis, we searched for transcripts dysregulated in Th17iv, Th17eae, and CD4eae 
cells compared to naïve CD4+T cells (Supplementary Table 2), and found that the great majority of IRG altered 
in CD4+T cells isolated from the CNS of EAE mice were present also in Th17 T cells after adoptive transfer 
(Fig. 1D), indicating that Th17 transcriptome well replicates the transcriptional changes of all CD4 cells during 
EAE in this model. Several cytokines (IL6, IL1b, IL18), chemokines (CCL2, CCL3, CCL5, CXCL9, CXCL10), and 
interferon regulatory factors (IRF4, IRF8) appeared among the dysregulated IRG in CD4eae and Th17eae. In vitro 
T cell differentiation towards the Th17 phenotype was characterized by several changes in Interferome which 
were mostly reproduced by Th17 cells isolated from EAE mice (Fig. 1E). Similarly to the EAE CNS transcriptomic 
profiles, we observed a clear and significant enrichment of IRG DEG in transcriptomes of CD4+ T lymphocytes 
from EAE animals or after in vitro Th17 differentiation (Table 1). Overall, we found robust evidence of IRG dys-
regulation in both CNS and CD4+ T cells of experimental MS.
Transcriptomic analysis of Interferome in MS. To verify dysregulation of Interferome in human MS, 
we retrieved human IRG from the online database7, mapped them to the relative array probe identifiers, isolated 
their expression levels from PBMC transcriptomes of CIS, RR-MS, PP-MS, SP-MS subjects and healthy individ-
uals (Fig. 2A), and conducted differential expression analysis to evaluate whether the probes corresponding to 
IRG were dysregulated at distinct clinical phases of disease compared to healthy controls. After applying false 
discovery rate corrected P-value threshold <0.05, we defined 250 differentially expressed probes in CIS, 220 in 
RR-MS, 480 in PP-MS and 409 in SP-MS respectively (Supplementary Table 3), with several of them dysregulated 
in at least 2 disease forms (Fig. 2B). Notably, 21 IRG were dysregulated in all disease groups compared to the 
healthy population (Fig. 2B) and direction of dysregulation was conserved in all cases (Fig. 2C). Specifically, the 
transcripts for ATM, BRD8, PURA, SMARCA3, SIRT4, RAF3IP3, VAMP1, and XPC were downregulated, while 
those for ADM, ARRB1, ASGR1, AQP9, BTBD14A, CDKN2D, DNASE2, GNA15, GPI, HNMT, IRAK3, KIF1B, 
NLRP3, NRG1, and TLR6 were upregulated under disease compared to healthy subjects. To evaluate whether MS 
transcriptome was enriched in dysregulated IRG, we measured the frequency of differential expression in the list 
of expressed IRG and in the global transcriptome for each MS form (Table 2), and calculated whether the fre-
quency of dysregulation of IRG was significantly higher in the IRG list than the expected frequency of differential 
regulation in a random selection of transcripts from the whole transcriptome. As shown in Table 2, IRG DEG 
enrichment was significant in RR-MS and not in the early phases of disease or the progressive MS population. 
Considering the high frequency of dysregulated Interferome in RR-MS, we further checked the expression of 
dysregulated IRG in PBMC of RR-MS in a distinct case-control cohort for which whole genome transcriptome 
was generated by Affymetrix arrays (Fig. 3A), and validated a total of 100 IRG DEG with concordant regula-
tion compared to healthy subjects in both independent cohorts measured with distinct array platforms (Fig. 3A 
and Supplementary Table 3). Gene ontology analysis unraveled significant enrichment in genes playing a role in 
NFkB pathway, immune defense, and apoptosis (Fig. 3B). Overall, several IRG changed expression at distinct MS 
stages, part of them were concordantly regulated in all MS forms, but alterations in Interferome were significantly 
enriched only in RR-MS.
IFN-beta modulates dysregulated IRG in RR-MS. To check whether IFN-beta treatment modulates 
baseline dysregulation of Interferome in RR-MS, we recovered the expression values of the 100 validated IRG 
in RR-MS from a published dataset8 comprising PBMC transcriptomic profiles from 50 RR-MS subjects under 
IFN-beta treatment for less than three years, 43 RR-MS patients under IFN-beta treatment for more than 3 years 
and 141 untreated RR-MS subjects (Fig. 3A). Importantly, 53 of 100 dysregulated IRG at baseline were targeted by 
IFN-beta treatment (Fig. 3C and Supplementary Table 4), with some transcripts counter-regulated (e.g. ARRB1, 
CHP1, IRAK3) and others further sustained (e.g. APLP2, BLVRA, CD86) under IFN-beta treatment. Down reg-
ulation of ARRB1 and CHP1 upon IFN treatment was validated by quantitative real time PCR in independent 
cohorts of IFN-beta-treated and untreated RR-MS patients (Fig. 3D). Further, short in vitro exposure to IFN-beta 













Chi square (Yate’s 
correction) P-value Z-score
D20_Sc 575 4022 14.29 1052 16589 6.34 563.9 0.00001 23.7
D40_Sc 858 4022 21.33 2983 16589 17.98 40.12 0.00001 6.35
Th17iv 1926 4147 46.44 7704 19149 40.2 84.60 0.00001 9.21
Th17eae 2614 4147 63.03 10556 19014 55.5 120.9 0.00001 11.01
CD4eae 2725 4147 65.71 11698 18978 61.6 36.96 0.00001 6.09
Table 1. Probability of IRG DEG enrichment in CNS and CD4 T lymphocytes during experimental 
neuroinflammation. DEG = differentially expressed gene; Sc = Spinal cord; eae = experimental autoimmune 
encephalomyelitis; Th17iv = in vitro differentiated T helper 17 cells.
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Discussion
In this study we provide evidence for transcriptional dysregulation of Interferome in the spinal cord of experi-
mental MS, in the CNS-infiltrating encephalitogenic mouse T lymphocytes and in the peripheral blood mononu-
clear cells of human subjects with distinct stages and clinical courses of multiple sclerosis.
We have recently reported the selective dysregulation of MS risk genes in peripheral blood of MS patients9. 
Interestingly, some of them play a role in IFN-mediated pathways, e.g. TYK2 and STAT4, and show aberrant 
expression in MS when compared to the healthy population, with TYK2 upregulated in PBMC from progressive 
Figure 2. (A) Flow chart for the human PBMC transcriptomics study at distinct MS stages. (B) Number of 
common and unique IRG DEG for each disease stage. (C) Fold change heatmap representing significantly 













Chi square (Yate’s 
correction) P-value Z-score
CIS 250 2385 10.48 1010 10314 9.79 1.570 0.2101 1.29
RR-MS 220 2385 9.22 764 10314 7.4 14.59 0.0001 3.86
PP-MS 480 2385 20.12 2039 10314 19.76 0.220 0.6388 0.49
SP-MS 409 2385 17.14 1854 10314 17.97 1.366 0.2425 −1.19
Table 2. Probability of IRG DEG enrichment at distinct stages of multiple sclerosis. HC = Healthy controls; 
CIS = clinically isolated syndrome; RR-MS = Relapsing-Remitting multiple sclerosis; PP-MS = Primary 
progressive multiple sclerosis; SP-MS = Secondary progressive multiple sclerosis; DEG = differentially 
expressed genes.
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MS and STAT4 downregulated in early and progressive stages of MS9. These data indicate that single risk genes 
involved in IFN signaling may be dysregulated in MS, and that this phenomenon is not necessarily conserved 
throughout all MS stages, raising the hypothesis that Interferome may be characterized by transcriptomic changes 
specific to disease type. Among several reports indicating transcriptional dysregulation induced by IFN-beta 
treatment in blood cells of MS patients10–13, a couple of studies suggest that expression of some type I IFN regu-
lated genes may be dysregulated at baseline and correlate with biological response to IFN-beta therapy14–16. No 
study has however provided the systematic analysis of Interferome in treatment-naïve MS subjects at distinct 
stages of disease. To this end we have exploited the collection of gene expression profiles in response to interferons 
Figure 3. (A) Flow chart for the human PBMC transcriptomics studies in RR-MS. (B) Significant Gene 
Ontology terms relative to the 100 validated IRG DEG in RR-MS. (C) Fold change heatmap representing 
the dysregulated IRG at baseline in RR-MS (first column) which are targeted in vivo by IFN-beta treatment 
(second and third columns). (D) ARRB1 and CHP1 transcript levels in PBMC from a novel independent cohort 
of untreated (NT) RR-MS and IFN-beta treated RR-MS as detected by quantitative PCR. **p-value < 0.01, 
***p-value < 0.001 (E) ARRB1 and CHP1 transcript levels in PBMC from RR-MS subjects stimulated in vitro in 
absence (NT) or presence of IFN-beta, *p-value < 0.05, **p-value < 0.01.
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provided by the Interferome database and mapped Interferome changes in experimental and human MS. Initially 
we have verified whether IRG transcriptome was enriched in the spinal cord at the acute (20 dpi) and chronic (40 
dpi) phases of EAE, in in vitro differentiated Th17 cells, and in Th17 and CD4+ T cells isolated from EAE CNS 
compared to controls. Our data clearly demonstrate that CNS neuroinflammation and T cell pathogenicity are 
characterized by massive changes in Interferome transcription, which is consistent with the known contribution 
of Type I and Type II interferons to the disease17.
The analysis of human PBMC transcriptomes has highlighted 21 concordantly regulated IRG transcripts at all 
MS stages compared to healthy controls, indicating that the disease is characterized by convergence towards some 
common IRG targets. Among them, for example we describe transcriptional upregulation of Nod-like recep-
tor family pyrin domain containing 3 (NLRP)-3, a member of the inflammasome complex, and beta-arrestin-1 
(ARRB1) a cytosolic protein essential for CD4+ T cell survival18, two genes whose products support the devel-
opment of experimental encephalomyelitis18,19. In addition, several IRG are dysregulated at distinct MS stages, 
underlying that differential expression of Interferome is not a completely stable feature throughout the disease. 
For instance, IRF1 supports EAE expression20 and is upregulated in PBMC from SP-MS subjects and not other 
disease stages. This observation opens to the possibility that immune cells at distinct MS stages display differ-
ences in the response to IFN, a hypothesis which deserves further investigation. When verifying the frequency 
of Interferome dysregulation at distinct MS courses, we have ascertained its significant enrichment in RR-MS, 
indicating that the relapsing-remitting form of disease is extremely characterized by transcriptional changes in 
IRG. Notably, 100 IRG dysregulations in RR-MS have been validated in an independent case-control cohort 
measured with a distinct array platform, and several of them have been already associated with MS pathogenesis. 
For instance, Caspase (CASP)-1, also known as interleukin 1 beta converting enzyme, regulates inflammatory 
processes during EAE21 and has been already shown to be upregulated in MS blood22. In harmony with the pub-
lished findings, we confirm overexpression of CASP1 transcript in PBMC of RR-MS compared to healthy sub-
jects. Further, S100A9, a member of S100 protein family, is strongly expressed in several inflammatory disorders 
and promotes the recruitment of immune cells to sites of tissue damage23. Its expression increases in the CNS of 
EAE mice24 and our study at 40dpi), in CD4+ Th17 T lymphocytes isolated from the CNS of EAE animals and in 
peripheral blood of RR-MS (our study). Another dysregulated IRG identified in our study is MAF, a transcription 
factor critical for Th17 T cell differentiation25. It is one of the proposed MS risk genes whose expression is upreg-
ulated in RR-MS blood9, and in pathogenic T lymphocytes from EAE CNS (this study).
Considering the overrepresentation of dysregulated IRG in RR-MS, we have verified whether IFN-beta ther-
apy targets the impaired expression of disease-associated IRG in RR-MS and found that the levels of 53 out of 
100 IRG dysregulated in treatment-naïve patients change under IFN-beta treatment. This analysis has led to the 
identification of several disease-associated transcripts that may serve as markers of biological activity of IFN-beta 
in vivo and potential novel targets for MS treatment. Further ex vivo and in vitro validations have been performed 
for ARRB1 and CHP1, whose gene product inhibits the transcriptional activity of Nuclear Factor of Activated T 
cells26. Their transcripts are upregulated in PBMC from treatment-naive RR- MS patients compared to healthy 
controls. Interestingly, our in vitro assays have shown that a short in vitro exposure to IFN-beta can induce rever-
sal regulation of ARRB1 and CHP1 transcripts in RR-MS immune cells. Further, we provide evidence that treat-
ment of RR-MS with IFN-beta counterbalances ARRB1 and CHP1 dysregulation present at baseline.
Overall, we demonstrate dysregulation of Interferome in experimental and human MS and describe novel 
IRG signatures at distinct stages of disease which can be partly targeted by IFN-beta treatment in vivo. The cor-
relation between Interferome dysregulation at baseline and clinical response to IFN-beta treatment is missing at 
this stage, but can be further addressed in future prospective studies. Anyway, our analyses provide the scientific 
community fundamental knowledge about the specificities of the IRG profiles at distinct MS stages and identify 
novel potential therapeutic targets in MS.
Materials and Methods
Human subjects and peripheral blood mononuclear cell (PBMC) preparation. Investigations were con-
ducted according to the principles expressed in the Declaration of Helsinki and after approval of the Ethics Committee 
of S. Raffaele and S. Andrea Hospitals, and peripheral blood was drawn after signing of the informed consent. MS 
subjects were diagnosed according to McDonald criteria27, were not suffering from any acute or chronic inflammatory 
diseases or other autoimmune disorders, and had not started any immunomodulatory therapy for MS unless where 
indicated. Demographic and clinical data of enrolled patients are listed in Table 1 of ref.9 and Supplementary Table 1 
of the current manuscript. PBMC were isolated using a discontinuous density gradient (Lympholyte-H, Ficoll-Paque 
Cederlane). Viable cells were counted by Trypan Blue (Sigma-Aldrich, Milan, Italy) exclusion.
PBMC stimulation with IFN-beta. For in vitro analyses, PBMC were resuspended in RPMI 1640 supple-
mented with 10% fetal bovine serum (BioWhittaker Europe), penicillin and streptomycin, and L-glutamine (Gibco), 
and cultured for 16 hours in presence or absence of 50 pM recombinant IFN-β1a (Betaferon, Bayer Pharma).
Experimental Autoimmune Encephalomyelitis (EAE), collection of CNS tissues and RNA prepa-
ration. C57BL/6 female mice were purchased from Charles River Laboratories (Calco, Italy), and housed in the 
institutional animal house. All procedures involving animals were performed according to guidelines authorized by 
the local institutional ethical animal committee and the Italian General Direction for Animal Health at the Ministry of 
Health. EAE was induced in 8 week-old C57BL/6 mice by subcutaneous immunization with 200 µg MOG35-55 peptide 
(Espikem, Florence, Italy) in complete Freund’s adjuvant containing 8 mg/ml Mycobacterium tuberculosis (strain 
H37Ra; DIFCO, BD, Buccinasco, Italy). Pertussis toxin (500 ng, Sigma-Aldrich) was injected on the day of the immu-
nization and two days later. Animals were monitored daily and scored as previously described28,29. At sacrifice EAE 
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and naïve mice were anaesthetized and perfused, spinal cords were isolated and used for transcriptomics studies. RNA 
was extracted by TRIzol Reagent (Thermo Fischer Scientific, Monza, Italy) following the manufacturer’s protocol.
Generation and analysis of Microarray Datasets. Spinal cord RNA from 3 EAE mice at day 20 
post-immunization (dpi), 3 EAE mice at day 40 post-immunization and 8 age-matched naïve mice were used 
for the mouse CNS microarray experiment. RNA was checked for integrity at Bioanalyzer 2100 (Agilent, Milan, 
Italy), converted to cRNA and hybridized on Affymetrix Gene Chip Mouse Genome 430 2.0 arrays expression 
arrays. Data were deposited at EBI Array express database (accession number: E-MTAB-5255). Affymetrix Gene 
Chip Operating Software was used to extract the raw data, which were then processed by robust multi-array 
average (RMA) algorithm in Bioconductor30 and keeping genes with multiple probes as individual transcripts. 
Transcriptomics data relative to mouse CD4 T lymphocytes were retrieved from Gene expression omnibus (GEO) 
database under the accession number GSE 570986. This dataset comprised three biological samples for each of 
the following groups: CD4+ CD62L+ naïve myelin-specific T lymphocytes before (T naïve) and after in vitro Th17 
differentiation (Th17 iv), CD4+ myelin-reactive Th17 T lymphocytes isolated after adoptive transfer from the 
CNS of EAE mice (Th17eae), CD4+ T lymphocytes isolated from the CNS of EAE mice after active immunization 
(CD4eae)6. Mouse CD4 T cell transcriptomic data were generated with Agilent Genome Microarray 4 × 44 K v2 
and all the raw data were processed using RMA algorithm in Bioconductor.
The human PBMC microarray datasets analyzed in this study were published in a recent paper of our group9 
and deposited at EBI Array express database. E-MTAB-4890 dataset was generated by Illumina Human Ref-8 v2 
microarrays and contained PBMC transcriptomes of 46 CIS, 52 RR-MS, 23 PP-MS, 21 SP-MS patients, and 40 
healthy controls (HC), while E-MTAB-5151 was generated with Affymetrix Gene Chip Human Genome U133 
plus 2.0 Arrays and comprised PBMC transcriptomes of 21 RR-MS and 27 healthy subjects. The Genome Studio 
GX software was used to extract the Illumina raw data, which were then background subtracted by nec method 
and normalized by cubic spline normalization as implemented in the software. Probes correlating with age in the 
healthy population were removed. Regarding the Affymetrix dataset, all the necessary pre-processing steps were 
performed using RMA algorithm present in the Affy package in Bioconductor, and keeping genes with multiple 
probes as individual transcripts. To assess whether IFN-beta treatment was targeting IRG expression in PBMC 
from RR-MS, we analyzed part of the PBMC transcriptome dataset published in ref.8, generated with Affymetrix 
Gene Chip Human Genome U133 plus 2.0 and composed of 128 IFN-beta treated and 141 untreated RR-MS 
subjects. All the raw data were pre-processed using RMA algorithm in the Affy package.
Probes with a mean intensity value lower than 100 in all experimental groups in both mouse and human 
studies were filtered out. To identify differentially expressed genes (DEG) we performed E-bayes statistics using 
Limma package in R Bioconductor30.
Collection of IRG and their relative gene expression data. 3855 human and 4081 mouse IRG were 
systematically collected from Interferome (version 2.01, update as of March 2015, http://interferome.its.monash.
edu.au/interferome/home.jspx), a manually curated database for interferon regulated genes identified in tran-
scriptomics studies7. All the filtered probes in the Illumina PBMC dataset were submitted to DAVID gene ID con-
version tool31 to retrieve Ensemble and gene symbol identifiers and isolate the probes relative to IRG. As further 
control, the same probe list was submitted to biomaRt ID conversion package in R Bioconductor32. Similarly, for 
the human/mouse Affymetrix or Agilent datasets IRG were annotated to the corresponding probes by biomaRt 
ID conversion package in R Bioconductor.
Frequency of dysregulated Interferome during neuroinflammation. To verify whether MS or EAE 
transcriptomes were enriched in dysregulated IRG, we measured the frequency of differential expression (DE) 
in IRG list and in the global transcriptome, and verified whether the frequency of IRG DEG was significantly 
higher in the IRG list than the expected frequency of dysregulation in a random selection of transcripts from the 
database by chi-square test with Yates’s correction in Graph Pad. Z score was calculated by Z = r-n ((R/N)/Sqrt 
(n(R/N) (1-R/N) (1-(n-1/N-1))33, where R is the number of dysregulated probes in the global transcriptome, N is 
the total number of expressed probes in the global transcriptome, r is the number of differentially expressed IRG 
probes and n is the total number of expressed IRG probes.
Gene Ontology enrichment analysis. Genecodis program34 was used to search for Gene Ontology bio-
logical processes enriched in the genelist and selected those terms passing the FDR-corrected p-value threshold of 
0.05 and containing three DEG. The database was annotated with approximately 95% of the genes in our gene list.
RNA extraction, cDNA synthesis, quantitative PCR. DNase I-treated total RNA was purified 
from ex vivo isolated or in vitro stimulated PBMC using the RNeasy Mini Kit (Qiagen, Valencia, CA), and 
reverse-transcribed by the Murine Leukaemia Virus Reverse Transcriptase (Invitrogen Life Technologies, 
Carlsbad, CA) following the manufacturers’ protocol. Real time PCR for target genes was conducted with TaqMan 
gene expression assays (Life Technologies, Monza, Italy) corresponding to the gene sequence recognized by the 
array probe. Thymosin Beta 10 (TMSB10) or Proteasome Subunit Beta 1 (PSMB1) were used as housekeeping 
genes due to their low coefficient of variation in the Illumina human transcriptomic dataset. Housekeeping genes 
with expression levels similar to those of the target genes were chosen. Target gene expression data were expressed 
as percentage of the housekeeping gene as already described9,35.
Statistical analysis. Normality of data distribution was assessed by Kolmogorov–Smirnov statistics. 
Unpaired t-test (in case of normal distribution) or non-parametric Mann–Whitney U test (in case of non-normal 
distribution) was performed to compare means between independent groups. Paired t-test was applied to 
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determine the significance of ARRB1 and CHP1 expression differences in vitro in absence or presence of IFN-beta 
stimulation. All the p-values were two-sided and subjected to a significance threshold of 0.05.
Data Availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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